Elevation of intraocular pressure after inadvertent dexamethasone implant injection into the lens

Lee, Kihwang; Park, Aram; Jang, Se-Ran; Younghae, Chung

doi:10.1016/j.jcjo.2015.12.022

Cited by 8 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitrectomy may be required if vitreous is encountered [ 5 , 6 , 8 ]. However, our case reinforces that capsular violations are not necessarily surgically problematic and a single-piece IOL can be safely placed in the capsule without additional fixation techniques or vitreoretinal surgery [ 2 ].…”

Section: Discussionsupporting

confidence: 60%

“…Prior case reports of intralenticular Ozurdex that received no intervention for 10 months reveal the potential stability of the implant inside the crystalline lens. These patients had stable vision with no or minimal progression of a cataract [ 1 , 2 ]. Although there was no IOP exacerbation following Ozurdex in our patient with ocular hypertension, IOP elevation has been previously reported, and it may be an indication for lens removal even in the absence of cataract [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

“…These patients had stable vision with no or minimal progression of a cataract [ 1 , 2 ]. Although there was no IOP exacerbation following Ozurdex in our patient with ocular hypertension, IOP elevation has been previously reported, and it may be an indication for lens removal even in the absence of cataract [ 2 ]. To our knowledge, the longest period an intralenticular Ozurdex had been followed prior to this case was 11 months [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

“…Most surgical approaches involve cataract extraction with concurrent removal of the implant [ 2 , 4 , 8 , 11 ]. In some cases, the implants have been repositioned to the posterior segment intraoperatively [ 6 , 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…It is delivered via a prepackaged 22-gauge injection device. The literature reveals previous cases of inadvertent intralenticular administration of Ozurdex [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ]. We report the case of a 60-year-old woman who was found to have an Ozurdex implant in the crystalline lens of the left eye in the setting of previously treated proliferative diabetic retinopathy with refractory diabetic macular edema (DME).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Intralenticular Ozurdex® – One Year Later

Regan

Blake

Lukowski

et al. 2017

Case Rep Ophthalmol

View full text Add to dashboard Cite

Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

show abstract